-
选择最佳的控制性促排卵(controlled ovarian stimulation, COS)方案获得合适数量的优质卵母细胞是体外受精-胚胎移植(IVF-ET)成功的关键。目前,COS多采用促性腺激素(Gn)诱导多卵泡发育,并通过GnRH类似物包括促性腺激素释放激素激动剂(gonadotropin-releasing hormone agonist, GnRHa)和拮抗剂(gonadotropin-releasing hormone antagonist, GnRH-A)抑制早发LH峰。GnRH-A方案因Gn用量少、刺激时间短、安全、无“短时激发效应”、病人依从性高、卵巢过度刺激综合征(ovarian hyperstimulation syndrome,OHSS)风险低等优点[1],近年已被越来越多应用于临床。本研究旨在比较不同拮抗剂对COS及IVF-ET临床结局的影响。现作报道。
-
2组病人年龄、不孕年限、体质量指数(BMI)差异均无统计学意义(P>0.05)。西曲瑞克组基础促卵泡刺激素(bFSH)、Gn用量和拮抗剂使用时间均低于加尼瑞克组(P < 0.05),基础窦状卵泡数(bAFC)、抗苗勒管激素(AMH)及获卵数均高于加尼瑞克组(P < 0.05~P < 0.01),2组hCG日LH水平、早发LH峰率、卵子逃逸率、取卵周期移植率、优质胚胎率、种植率、临床妊娠率及早期流产率差异均无统计学意义(P>0.05)(见表 1、2)。
基本特征 西曲瑞克组
(n=377)加尼瑞克组
(n=166)t P 女方年龄/岁 29.54±4.08 30.19±4.45 1.66 >0.05 不孕年限/年 3.81±2.64 3.75±2.78 0.24 >0.05 BMI/(kg/m2) 23.00±3.81 22.86±3.11 0.42 >0.05 AMH/(ng/mL) 7.65±5.35 5.91±5.18 3.53 < 0.01 bFSH/(mIU/mL) 7.88±2.38 8.33±2.45 2.01 < 0.05 bLH/(mIU/mL) 6.12±3.73 5.50±3.23 1.86 >0.05 bAFC/枚 18.87±8.45 15.61±7.70 4.25 < 0.01 表 1 病人一般资料比较(x±s)
观察指标 西曲瑞克组(n=377) 加尼瑞克组(n=166) t P Gn用量/IU 1 681.36±674.80 1 944.97±933.30 3.71 < 0.01 拮抗剂使用时间/d 4.77±1.39 5.08±1.55 2.31 < 0.05 hCG日内膜/mm 11.54±2.82 11.20±2.69 1.31 >0.05 hCG日雌二醇(E2)/(pg/mL) 3 522.41±2 778.87 3 502.75±3 592.95 0.07 >0.05 hCG日LH/(mIU/mL) 3.33±2.17 3.52±1.95 0.97 >0.05 获卵数/枚 15.13±9.48 13.25±8.99 2.16 < 0.05 取卵周期移植率/% 48.81(184/377) 51.81(86/166) 0.42 >0.05 移植胚胎数/枚 1.95±0.22 1.97±0.18 1.03 >0.05 种植率/% 39.00(140/359) 38.46(65/169) 0.01 >0.05 优胚率/% 73.34(1 917/2 614) 74.05(776/1 048) 0.19 >0.05 临床妊娠率/% 57.07(105/184) 55.81(48/86) 0.04 >0.05 异位妊娠率/% 5.71(6/105) 2.08(1/48) 0.99 >0.05 早期流产率/% 13.33(14/105) 10.42(5/48) 0.26 >0.05 活产率/% 44.57(82/184) 41.86(36/86) 0.17 >0.05 早发LH峰率/% 1.86(7/377) 1.81(3/166) 0.09△ >0.05 卵子逃逸率/% 0.27 (1/377) 0(0/166) — >0.05▲ △示校正χ2值;▲示Fisher′s确切概率法 表 2 COS情况及临床结局比较(x±s)
不同拮抗剂体外受精-胚胎移植临床结局比较
Comparison of the clinical outcomes of different antagonists in vitro fertilization-embryo transfer
-
摘要:
目的比较拮抗剂方案中注射用醋酸西曲瑞克(西曲瑞克)与醋酸加尼瑞克(加尼瑞克)的体外受精-胚胎移植(IVF-ET)临床结局。 方法回顾性分析2017年1月至2018年3月采用拮抗剂方案行IVF/ICSI治疗543个周期的临床资料,按控制性促排卵过程中使用的促性腺激素释放激素拮抗剂的不同,分为西曲瑞克组和加尼瑞克组,比较2组控制性促排卵(COS)及体外受精-胚胎移植(IVF-ET)临床结局。 结果2组病人年龄、不孕年限、体质量指数差异无统计学意义(P>0.05)。西曲瑞克组基础促卵泡刺激素、促性腺激素用量和拮抗剂使用时间均低于加尼瑞克组(P < 0.05),基础窦状卵泡数、抗苗勒管激素及获卵数均高于加尼瑞克组(P < 0.05~P < 0.01),2组人绒毛膜促性腺激素日促黄体生成素(LH)水平、早发LH峰率、卵子逃逸率、取卵周期移植率、优质胚胎率、种植率、临床妊娠率及早期流产率差异均无统计学意义(P>0.05)。 结论拮抗剂方案中西曲瑞克与加尼瑞克具有相似的抑制早发LH峰效应和临床结局。 Abstract:ObjectiveTo compare the clinical outcomes between cetrorelix acetate(cetrorelix) and Ganirelix acetate(ganirelix) in vitro fertilization-emryo transfer(IVF-ET). MethodsThe clinical data of 543 IVF-ET cycles treated with IVF/ICSI program from January 2017 to March 2018 were retrospectively analyzed.The patients were divided into the cetrorelix group and ganirelix group according to the gonadotropin-releasing hormone antagonist types.The clinical outcomes of controlled ovarian stimulation(COS) and IVF-ET were compared between two groups. ResultsThe differences of the age, infertility years and body mass index between two groups were not statistically significant(P>0.05).The basal follicle-stimulating hormone level, gonadotropin dosage and antagonist duration in cetrorelix group were significantly higher than those in ganirelix group(P < 0.05).The number of basal sinusoid follicles, anti-mulller hormone and number of acquired eggs in cetrorelix group were higher than those in ganirelix group(P < 0.05 to P < 0.01).The differences of the chorionic gonadotropin and luteinizing hormone(LH) levels, LH peak rate of early onset, Oocyte escape rate, oocyte retrieval cycle transplantation rate, high quality embryo rate, implantation rate, clinical pregnancy rate and early abortion rate were not statistically significant(P>0.05). ConclusionsThe inhibitory effects on early LH peak and clinical outcomes of antagonist regiments of cetrorelix and ganirelix are similar. -
表 1 病人一般资料比较(x±s)
基本特征 西曲瑞克组
(n=377)加尼瑞克组
(n=166)t P 女方年龄/岁 29.54±4.08 30.19±4.45 1.66 >0.05 不孕年限/年 3.81±2.64 3.75±2.78 0.24 >0.05 BMI/(kg/m2) 23.00±3.81 22.86±3.11 0.42 >0.05 AMH/(ng/mL) 7.65±5.35 5.91±5.18 3.53 < 0.01 bFSH/(mIU/mL) 7.88±2.38 8.33±2.45 2.01 < 0.05 bLH/(mIU/mL) 6.12±3.73 5.50±3.23 1.86 >0.05 bAFC/枚 18.87±8.45 15.61±7.70 4.25 < 0.01 表 2 COS情况及临床结局比较(x±s)
观察指标 西曲瑞克组(n=377) 加尼瑞克组(n=166) t P Gn用量/IU 1 681.36±674.80 1 944.97±933.30 3.71 < 0.01 拮抗剂使用时间/d 4.77±1.39 5.08±1.55 2.31 < 0.05 hCG日内膜/mm 11.54±2.82 11.20±2.69 1.31 >0.05 hCG日雌二醇(E2)/(pg/mL) 3 522.41±2 778.87 3 502.75±3 592.95 0.07 >0.05 hCG日LH/(mIU/mL) 3.33±2.17 3.52±1.95 0.97 >0.05 获卵数/枚 15.13±9.48 13.25±8.99 2.16 < 0.05 取卵周期移植率/% 48.81(184/377) 51.81(86/166) 0.42 >0.05 移植胚胎数/枚 1.95±0.22 1.97±0.18 1.03 >0.05 种植率/% 39.00(140/359) 38.46(65/169) 0.01 >0.05 优胚率/% 73.34(1 917/2 614) 74.05(776/1 048) 0.19 >0.05 临床妊娠率/% 57.07(105/184) 55.81(48/86) 0.04 >0.05 异位妊娠率/% 5.71(6/105) 2.08(1/48) 0.99 >0.05 早期流产率/% 13.33(14/105) 10.42(5/48) 0.26 >0.05 活产率/% 44.57(82/184) 41.86(36/86) 0.17 >0.05 早发LH峰率/% 1.86(7/377) 1.81(3/166) 0.09△ >0.05 卵子逃逸率/% 0.27 (1/377) 0(0/166) — >0.05▲ △示校正χ2值;▲示Fisher′s确切概率法 -
[1] 朱洁茹, 欧建平, 邢卫杰, 等. GnRH激动剂长方案与GnRH拮抗剂方案在不同年龄组、不同反应人群中的新鲜周期临床结局比较[J]. 中山大学学报, 2017, 38(5): 8. [2] 靳镭, 徐蓓. 黄体生成素在卵泡发育中的作用及早卵泡期黄体生成素预处理[J]. 生殖医学杂志, 2014, 23(12): 4. [3] MOKHTAR S, SADEGHI MR, AKHONDI MM, et al. ART outcomes in GnRH antagonist protocol (Flexible) and long GnRH agonist protocol during early follicular phase in patients with polycystic ovary syndrome: A randomized Clinical Trial[J]. J Reprod Infertil, 2015, 16(3): 148. [4] TOFTAGER M, BOGSTAD J, BRYNDORF T, et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles[J]. Hum Reprod, 2016, 31(6): 1. [5] SAHIN S, SELCUK S, DEVRANOGLU B, et al. Comparison of long GnRH agonist versus GnRH antagonist protocol in poor responders[J]. Turk J Obstet Gynecol, 2014, 11(4): 203. doi: 10.4274/tjod.80090 [6] HOWLES CM.The place of gonadotrophin-releasing hormone antagonists in reproductive medicine[J]. Reprod Biomed Online, 2002, 4(3): 64. [7] REICHMAN DE, ZAKARIN L, CHAO K, et al. Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles[J]. Fertil Steril, 2014, 102(1): 99. doi: 10.1016/j.fertnstert.2014.04.010 [8] ZHANG D, XIA L, XU H, et al. Flexible low-dose gnrh antagonist protocol is effective in patients with sufficient ovarian reserve in IVF[J]. Front Endocrinol (Lausanne), 2018, 9: 767. doi: 10.3389/fendo.2018.00767 [9] BORM G, MANNAERTS B.Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group[J]. Hum Reprod, 2000, 15(7): 1490. doi: 10.1093/humrep/15.7.1490 [10] LAI Q, HU J, ZENG D, et al. Assessing the optimal dose for Cetrorelix in Chinese women undergoing ovarian stimulation during the course of IVF-ET treatment[J]. Am J Transl Res, 2014, 6(1): 78. [11] 田阳, 谢铁男, 扈聪, 等. 不同卵巢储备功能病人血清GnSAF水平比较[J]. 山东医药, 2016, 56(35): 3. [12] PECHSTEIN B, NAGARAJA VN, HERMANN R, et al. Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers[J]. J Clin Pharmacol, 2000, 40(3): 266. doi: 10.1177/00912700022008937 [13] OBERYE JJ, MANNAERTS BM, HUISMAN JA, et al. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part Ⅱ. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers[J]. Fertil Steril, 1999, 72(6): 1006. doi: 10.1016/S0015-0282(99)00414-8 [14] DUIJKERS IJ, KLIPPING C, WILLEMSEN WN, et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers[J]. Hum Reprod, 1998, 13(9): 2392. doi: 10.1093/humrep/13.9.2392